Antipyretic activity of N-acetylcysteine

Journal of Physiology and Pharmacology

Volumn 62, Issue 6, 2011, Pages 669-675

  Wrotek, S ^a   Jedrzejewski, T ^a   Potera Kram, E ^a   Kozak, W ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Biotelemetry; Body mass; Body temperature; Fever; Lipopolysaccharide; Motor activity; N acetylcysteine; Turpentine oil

Indexed keywords

ACETYLCYSTEINE; BACTERIUM LIPOPOLYSACCHARIDE; TURPENTINE;

ABSCESS; ANIMAL EXPERIMENT; ANTIPYRETIC ACTIVITY; ARTICLE; ASEPTIC ABSCESS; BODY TEMPERATURE; CIRCADIAN RHYTHM; CONTROLLED STUDY; FEVER; INFECTION; MOTOR ACTIVITY; NONHUMAN; RAT; TELEMETRY; WEIGHT REDUCTION;

ACETYLCYSTEINE; ANIMALS; ANTIPYRETICS; CIRCADIAN RHYTHM; FEVER; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR;

EID: 84856822204     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. De Vries N, De Flora S. N-Acetyl-L-cysteine. J Cell Biochem 1993; 17: 270-278.
2. Bonanomi L, Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis Suppl 1980; 111: 45-51.
3. Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed Pharmacother 1998; 42: 513-520.
4. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 6-20.
5. De Rosa SC, Zaretsky MD, Dubs J G, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000; 30: 915-929.
6. Breitkreutz R, Pittack N, Nebe CT, et al. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J Mol Med 2000; 78: 55-62.
7. Spada C, Treitinger A, Reis M, et al. The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment. Clin Chem Lab Med 2002; 40: 452-455.
8. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001; 57: 1515-1517.
9. De Mattia G, Bravi MC, Laurenti O, et al. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia 1998; 41: 1392-1396.
10. Svendsen JH, Klarlund K, Aldershvile J, Waldorff S. N-Acetylcysteine modifies the acute effects of isosorbide-5-mononitrate in angina pectoris patients evaluated by exercise testing. J Cardiovasc Pharmacol 1989; 13: 320-323.
11. Estensen RD, Levy M, Klopp SJ, et al. N-Acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. Cancer Lett 1999; 147: 109-114.
12. Parr GD, Huitson A. Oral fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest 1987; 81: 341-348.
13. Ratjen F, Wonne R, Posselt HG, Stover B, Hofmann D, Bender SW. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 1985; 144: 374-378.
14. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92: 609-623.
15. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977; 2: 432-434.
16. Prescott L. Oral or intravenous N-acetylcysteine for acetaminophen poisoning? Ann Emerg Med 2005; 45: 409-413.
17. Kozak W, Kluger MJ, Tesfaigzi J, et al. Molecular mechanisms of fever and endogenous antipyresis. Ann NY Acad Sci 2000; 917: 121-134.
18. Kluger MJ, Kozak W, Conn CA, Leon LR, Soszynski D. The adaptive value of fever. Infec Dis Clin North Am 1996; 10: 1-21.
19. Roberts NJ. Impact of temperature elevation of immunologic defense. Rev Infect Dis 1991; 13: 462-472.
20. Roberts NJ. The immunological consequences of fever. In: Fever: Basic Mechanisms and Management. Mackowiak P.A. (ed). Raven Press, New York 1991; p.125.
21. Kluger MJ, Ringler DH, Anver MR. Fever and survival. Science 1975; 188: 166-168.
22. Wrotek SE, Kozak WE, Hess DC, Fagan SC. Treatment of fever after stroke: conflicting evidence. Pharmacotherapy 2011; 31: 1085-1091.
23. Sulter G, Elting JW, Maurits N, Luijckx GJ, De Keyser J. Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. Cerebrovasc Dis 2004; 17: 118-122.
24. Dippel DW, van Breda EJ, van der Worp HB, et al. Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. PJ; PISA-Investigators. BMC Cardiovasc Disord 2003; 3: 2.
25. Kasner SE, Wein T, Piriyawat P, et al. Acetaminophen for altering body temperature in acute stroke: a randomized clinical trial. Stroke 2002; 33: 130-134.
26. Koennecke HC, Leistner S. Prophylactic antipyretic treatment with acetaminophen in acute ischemic stroke: a pilot study. Neurology 2001; 57: 2301-2303.
27. Kozak W, Klir JJ, Conn CA, Kluger MJ. Attenuation of lipopolysaccharide fever in rats by protein kinase C inhibitors. Am J Physiol 1997; 273: R873-R879.
28. Lim CL, Wilson G, Brown L, Coombes JS, Mackinnon LT. Pre-existing inflammatory state compromises heat tolerance in rats exposed to heat stress. Am J Physiol Regul Integr Comp Physiol 2007; 292: R186-R194.
29. Bijarnia RK, Kaur T, Singla SK, Tandon C. Oxalate-mediated oxidant-antioxidant imbalance in erythrocytes: role of N-acetylcysteine. Hum Exp Toxicol 2009; 28: 245-251.
30. Bennett IL Jr, Petersdorf RG, Keene WR. Pathogenesis of fever: evidence for direct cerebral action of bacterial endotoxins. Trans Assoc Am Physicians 1957; 70: 64-73.
31. Cooper AL, Brouwer S, Turnbull AV, et al. Tumor necrosis factor-alpha and fever after peripheral inflammation in the rat. Am J Physiol 1994; 267: 1431-1436.
32. Kozak W, Kluger MJ, Soszynski D, Conn CA, et al. IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Ann N Y Acad Sci 1998; 856: 33-47.
33. Kozak W, Soszynski D, Rudolph K, Conn CA, Kluger MJ. Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation. Am J Physiol 1997; 272: 1298-1307.
34. Gao W, Schmidtko A, Wobst I, Lu R, Angioni C, Geisslinger G. Prostaglandin D2 produced by hematopoietic prostaglandin D synthase contributes to LPS-induced fever. J Physiol Pharmacol 2009; 60: 145-150.
35. Schubert SY, Neeman I, Resnick N. A novel mechanism for the inhibition of NFκB activation in vascular endothelial cells by natural antioxidants. FASEB J 2002; 16: 1931-1933.
36. Paintlia MK, Paintlia AS, Singh AK, Singh I. Attenuation of lipopolysaccharide-induced inflammatory response and phospholipids metabolism at the feto-maternal interface by N-acetyl cysteine. Pediatr Res 2008; 64: 334-339.
37. Lee JJ, Huang WT, Shao DZ, Liao JF, Lin MT. Blocking NF-κB activation may be an effective strategy in the fever therapy. Jpn J Physiol 2003; 53: 367-375.
38. Kozak W, Wrotek S, Kozak A. Pyrogenicity of CpG-DNA in mice: role of interleukin-6, cyclooxygenases and nuclear factor-κB. Am J Physiol 2006; 290: R871-R880.
39. Palacio JR, Markert UR, Martinez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res 2011; 60: 695-704.
40. Lima Trajano ET, Sternberg C, Caetano M, et al. Endotoxin-induced acute lung injury is dependent upon oxidative response. Inhal Toxicol 2011; 23: 918-926.
41. Kozak W, Kozak A. Differential role of nitric oxide synthase isoforms in fever of different etiologies: studies using Nos gene-deficient mice. J Appl Physiol 2003; 94: 2534-2544.
42. Pechanova O, Kunes J, Dobesova Z, Vrankova S, Zicha J. Contribution of neuronal nitric oxide (NO) synthase to N-acetylcysteine-induced increase of NO synthase activity in the brain of normotensive and hypertensive rats. J Physiol Pharmacol 2009; 60(4): 21-5.